Radiology, Vol 186, 37-44, Copyright © 1993 by Radiological Society of North America

ARTICLES

Brain metastases from non-central nervous system tumors: evaluation with PET

LK Griffeth, KM Rich, F Dehdashti, JR Simpson, MJ Fusselman, AH McGuire and BA Siegel
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO 63110.

Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) was performed in 19 patients with brain metastases from non- central nervous system (CNS) neoplasms and one patient with a primary CNS lymphoma. Various histopathologic types were represented by the primary neoplasms in the patients with metastases. Only 21 of the 31 lesions (68%) were detected with FDG PET as discrete, metabolically active foci (relative to surrounding structures). Six of the nondetected lesions may have been nondiscernible owing to their small size and/or isointensity relative to closely apposed normal gray matter. However, four lesions of at least 1.2 cm in diameter showed frankly decreased FDG accumulation relative to normal brain. These findings suggest that studies of FDG accumulation by a variety of non- CNS neoplasms and their CNS metastases are in order and that extrapolation of the successes of FDG PET in imaging of primary glial tumors to imaging of brain metastases should proceed with caution.

This article has been cited by other articles:

				Y. Ohno, H. Koyama, Y. Onishi, D. Takenaka, M. Nogami, T. Yoshikawa, S. Matsumoto, Y. Kotani, and K. Sugimura Non-Small Cell Lung Cancer: Whole-Body MR Examination for M-Stage Assessment--Utility for Whole-Body Diffusion-weighted Imaging Compared with Integrated FDG PET/CT Radiology, August 1, 2008; 248(2): 643 - 654. [Abstract] [Full Text] [PDF]

				G. A. Silvestri, M. K. Gould, M. L. Margolis, L. T. Tanoue, D. McCrory, E. Toloza, and F. Detterbeck Noninvasive Staging of Non-small Cell Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 178S - 201S. [Abstract] [Full Text] [PDF]

				K. E. Posther, L. M. McCall, D. H. Harpole Jr., C. E. Reed, J. B. Putnam Jr., V. W. Rusch, and B. A. Siegel Yield of Brain 18F-FDG PET in Evaluating Patients with Potentially Operable Non-Small Cell Lung Cancer J. Nucl. Med., October 1, 2006; 47(10): 1607 - 1611. [Abstract] [Full Text] [PDF]

				E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]

				C. E. Reed, D. H. Harpole, K. E. Posther, S. L. Woolson, R. J. Downey, B. F. Meyers, R. T. Heelan, H. A. MacApinlac, S.-H. Jung, G. A. Silvestri, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1943 - 1951. [Abstract] [Full Text] [PDF]

				M. Essig, M. Waschkies, F. Wenz, J. Debus, H. R. Hentrich, and M. V. Knopp Assessment of Brain Metastases with Dynamic Susceptibility-weighted Contrast-enhanced MR Imaging: Initial Results Radiology, July 1, 2003; 228(1): 193 - 199. [Abstract] [Full Text] [PDF]

				E. M. Rohren, J. M. Provenzale, D. P. Barboriak, and R. E. Coleman Screening for Cerebral Metastases with FDG PET in Patients Undergoing Whole-Body Staging of Non-Central Nervous System Malignancy Radiology, January 1, 2003; 226(1): 181 - 187. [Abstract] [Full Text] [PDF]

				J.F. Vansteenkiste and S.G. Stroobants The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology Eur. Respir. J., April 1, 2001; 17(4): 802 - 820. [Abstract] [Full Text] [PDF]